Literature DB >> 21483261

Risks and benefits of multiple sclerosis therapies: need for continual assessment?

Bernd C Kieseier, Heinz Wiendl, Hans-Peter Hartung, Verena-Isabell Leussink, Olaf Stüve.   

Abstract

PURPOSE OF REVIEW: The aim is to describe and discuss the ongoing debate on how to balance an increase in clinical efficacy against a heightened risk of developing serious side-effects, as has surfaced recently with some novel therapies for relapsing forms of multiple sclerosis. RECENT
FINDINGS: New therapies are emerging that differ with regard to their mechanism of action, their mode of administration, their side-effect profile and the clinical benefits that they offer to patients in comparison with established therapeutic modalities in multiple sclerosis. Treating physicians will need to make choices on the best treatments for their patients on the basis of limited experience. This process requires optimal assessment of risks and benefits.
SUMMARY: Careful assessment of the risk-benefit profile of the various options may allow treatment choices and perhaps ensure that patients obtain the most benefit from treatment without being exposed to unnecessary risk.

Entities:  

Mesh:

Year:  2011        PMID: 21483261     DOI: 10.1097/WCO.0b013e32834696dd

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  3 in total

1.  Decision making in MS: factors affecting engagement in treatment choices.

Authors:  Nils Muhlert
Journal:  Funct Neurol       Date:  2016 Jan-Mar

2.  Oral administration of the nitroxide radical TEMPOL exhibits immunomodulatory and therapeutic properties in multiple sclerosis models.

Authors:  Sarah Neil; Jaebong Huh; Victoria Baronas; Xinhui Li; Henry F McFarland; Murali Cherukuri; James B Mitchell; Jacqueline A Quandt
Journal:  Brain Behav Immun       Date:  2017-02-24       Impact factor: 7.217

Review 3.  Risk evaluation and monitoring in multiple sclerosis therapeutics.

Authors:  Michel C Clanet; Jerry S Wolinsky; Raymond J Ashton; Hans-Peter Hartung; Stephen C Reingold
Journal:  Mult Scler       Date:  2013-11-30       Impact factor: 6.312

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.